In this regard, effective therapeutic interventions for the prevention of arrhythmia/SCD in obesity would likely require chronic administration, which would render TCZ ineligible for the long-term treatment of chronic metabolic diseases and highlight the mechanistic relevance of selectively targeting IL-6 trans-signaling. This evidence concerns the gene IL6 and cardiac arrhythmia.